PPMD 2024: PTC to seek FDA approval of ataluren for DMD
PTC Therapeutics plans to soon ask the U.S. Food and Drug Administration (FDA) to approve ataluren as a treatment for Duchenne muscular dystrophy (DMD) caused by nonsense mutations. “We are thrilled to announce that we are moving forward with the submission of a new drug application for…